About Us

WHAT IS AGICC?

The Aptium Oncology GI Cancer Consortium (AGICC) is an innovative and focused full service research model created to enhance the state of care for GI cancer patients, with a goal of expediting the process of identifying and efficiently testing active new compounds for the treatment of GI cancers. Our ability to rapidly design and execute focused clinical trials in GI cancers will enhance our partner sponsors ability to make informed decisions on the development of their compounds. Ultimately, AGICC's goal is to serve as an important model for speeding time-to-market for drugs targeting all GI cancers.

This innovative model is the merger of full service operations with a select group of the best and brightest investigators from prestigious cancer centers around the country. Each member demonstrates clinical and translational research capabilities in GI cancers and shares a common commitment to exploring and creating new frontiers in GI cancer research.

AGICC builds upon the complementary strengths of the member institutions selected for the Consortium, each of which is funded via a competitive support grant to be used for expanding and supplementing their ongoing clinical and translational gastrointestinal cancer programs.